Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India

BACKGROUND AND AIMS: In clinical studies, sofosbuvir–velpatasvir has demonstrated high cure rates and favorable tolerability in patients chronically infected with chronic hepatitis C virus (HCV) of any genotype. We evaluated the effectiveness and safety of sofosbuvir–velpatasvir administered with mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Ajit, Duseja, Ajay, Kabrawala, Mayank, Amrose, Pradeep, Goswami, Bhadadev, Chowdhury, Abhijit, Sarin, Shiv Kumar, Koshy, Abraham, Hyland, Robert H., Lu, Sophia, Camus, Gregory, Stamm, Luisa M., Brainard, Diana M., Subramanian, G. Mani, Prasad, Madhura, Bhatia, Shobna, Shah, Samir R., Kapoor, Dharmesh, Shalimar, Saraswat, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418070/
https://www.ncbi.nlm.nih.gov/pubmed/30790229
http://dx.doi.org/10.1007/s12072-019-09927-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418070/
https://www.ncbi.nlm.nih.gov/pubmed/30790229
http://dx.doi.org/10.1007/s12072-019-09927-6

Ejemplares similares